心絞痛市場規模、佔有率和成長分析：按疾病類型、藥物類別、治療方法、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球心絞痛市場價值為 108.2 億美元，預計到 2025 年將成長至 112.9 億美元，到 2033 年將成長至 158 億美元，在預測期（2026-2033 年）內複合年成長率為 4.3%。

全球心絞痛市場受到冠狀動脈疾病（尤其是老年族群）日益成長的盛行率的顯著影響，這推動了對有效藥物和介入治療的需求。該市場涵蓋旨在控制症狀性缺血的藥物、診斷工具和介入器械，以應對與發病率和成本相關的重大醫療保健挑戰。治療策略正從單純緩解症狀轉向採用實證治療方法，尤其是在藥物釋放型支架和改進的診斷技術等創新技術的推動下。人工智慧的整合進一步強化了這一趨勢，透過先進的成像和即時監測，提高了檢測精度，並實現了個人化治療方案。隨著醫療保健系統向價值導向醫療模式轉型並投資於先進的診斷技術，對綜合診斷和治療路徑的需求持續成長，從而推動了市場的顯著擴張。

全球心絞痛市場的成長要素

全球心絞痛市場主要受各類藥物和介入器材供應增加的推動。這使得臨床醫生能夠為患者制定個人化的治療方案。這種個人化方法增強了患者的適應性，並促進了治療的持續依從性。近年來，藥物創新，例如耐受性較好的藥物和多樣化的給藥途徑，正在降低長期治療的障礙。此外，微創手術的進步也為以往選擇有限的患者拓展了治療選擇。這些治療選擇的拓展，從整體上促進了個人化護理計劃的實施，增強了臨床醫生的信心，並鼓勵更廣泛地採用基於指南的治療策略，從而維持了強勁的市場需求。

全球心絞痛市場的限制因素

全球心絞痛市場面臨許多限制因素，主要源自於創新藥物、先進醫療設備和特殊手術的高成本。這些成本給醫療系統和患者都帶來了沉重負擔，這限制了患者獲得新療法的機會。在預算限制和報銷模式不穩定的環境下，醫療服務提供者往往傾向於選擇更經濟的傳統療法，阻礙了尖端產品的推廣應用。此外，這些經濟障礙加劇了不同地區和人口在醫療資源取得方面的不平等，阻礙了產品的廣泛接受，並抑制了對供應和分銷網路的投資。所有這些因素共同限制了市場的整體成長潛力。

全球心絞痛市場趨勢

全球心絞痛市場正經歷著向數位化遠端監測和遠端醫療解決方案的顯著轉變，這徹底改變了心絞痛的治療方式。這種轉變實現了症狀的持續追蹤，促進了個性化治療路徑的製定，並有助於及時干預。醫療專業人員擴大利用穿戴式技術和患者報告結局（PRO）來客製化治療方案並最佳化用藥計劃，而無需患者定期前往醫院。整合式醫療模式日益普及，提高了患者的依從性和參與度，而技術提供者則優先考慮互通性和直覺的介面。這一趨勢不僅加強了患者與醫療服務提供者之間的溝通，而且與以價值為導向的醫療理念相契合，顯著改善了心絞痛等慢性疾病的管理。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球心絞痛市場規模：依疾病類型分類

• 穩定性心絞痛
• 不穩定型心絞痛
• 微血管性心絞痛
• Prinzmetal型心絞痛
• 其他

全球心絞痛市場規模：依藥物類別分類

• BETA受體阻斷劑
• 鈣離子通道阻斷劑
• 硝酸鹽
• 血管收縮素轉化酵素抑制劑
• 抗血小板藥物
• 其他

全球心絞痛市場規模：依治療方法

• 藥物治療
• 侵入性手術
  • 血管成形術和支架置入術
  • 冠狀動脈繞道手術手術
• 生活方式管理
• 其他

全球心絞痛市場規模：依最終用戶分類

• 醫院
• 專科診所
• 居家醫療環境
• 其他

全球心絞痛市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

全球心絞痛市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Novartis
• Pfizer
• Sanofi
• Bayer
• Gilead Sciences
• GlaxoSmithKline
• AstraZeneca
• Abbott Laboratories
• Johnson & Johnson
• Teva Pharmaceutical
• Sun Pharmaceutical
• Viatris
• Lupin
• Cipla
• Dr. Reddy's Laboratories
• Otsuka Pharmaceutical
• Torrent Pharmaceuticals
• Zydus Lifesciences
• Hikma Pharmaceuticals
• Amgen

結論與建議

Global Angina Market size was valued at USD 10.82 Billion in 2024 and is poised to grow from USD 11.29 Billion in 2025 to USD 15.8 Billion by 2033, growing at a CAGR of 4.3% during the forecast period (2026-2033).

The global angina market is significantly influenced by the increasing prevalence of coronary artery disease, particularly among the aging population, which drives the need for effective medical and interventional solutions. This market encompasses pharmaceuticals, diagnostic tools, and interventional devices aimed at managing symptomatic ischemia, addressing substantial healthcare challenges related to morbidity and costs. A shift has occurred from merely alleviating symptoms to employing evidence-based therapies, notably through innovations like drug-eluting stents and improved diagnostic techniques. The integration of AI enhances this landscape by enhancing detection accuracy and enabling personalized treatment plans via advanced imaging and real-time monitoring. As healthcare systems adapt to value-based care and invest in advanced diagnostics, the demand for comprehensive diagnostic-treatment pathways continues to grow, fostering significant market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Angina market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Angina Market Segments Analysis

Global angina market is segmented by disease type, drug class, treatment modality, end-user, distribution channel and region. Based on disease type, the market is segmented into Stable Angina, Unstable Angina, Microvascular Angina, Prinzmetal Angina and Others. Based on drug class, the market is segmented into Beta-Blockers, Calcium Channel Blockers, Nitrates, Angiotensin-Converting Enzyme Inhibitors, Anti-Platelet Agents and Others. Based on treatment modality, the market is segmented into Pharmacological Treatment, Invasive Procedures, Lifestyle Management and Others. Based on end-user, the market is segmented into Hospitals, Specialty Clinics, Homecare Settings and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Angina Market

The global angina market is significantly driven by the increased availability of various pharmacological classes and interventional devices, which empower clinicians to customize treatment pathways for patients. This tailored approach enhances patient compatibility and promotes ongoing adherence to therapies. Recent pharmaceutical innovations featuring agents that offer better tolerability and diverse delivery methods alleviate obstacles to long-term management. Additionally, advancements in minimally invasive procedures broaden therapeutic options for patients who had limited alternatives. Collectively, these expanded treatment choices facilitate individualized care plans, bolster clinician confidence, and promote the wider adoption of guideline-focused management strategies, thereby sustaining robust market demand.

Restraints in the Global Angina Market

The global angina market faces significant constraints primarily due to the high costs associated with innovative medications, advanced devices, and specialized procedural care. These expenses limit the affordability for both healthcare systems and patients, resulting in reduced access to newer therapeutic options. In environments with budget restrictions or unpredictable reimbursement models, healthcare providers tend to opt for older, more economical alternatives, which hampers the adoption of cutting-edge products. Additionally, the financial barriers contribute to disparities in access across different regions and demographic groups, impeding widespread acceptance and discouraging investment in supply and distribution networks. This scenario collectively stifles overall market growth potential.

Market Trends of the Global Angina Market

The Global Angina market is witnessing a significant trend towards digital remote monitoring and telehealth solutions, revolutionizing the approach to angina management. This shift enables continuous tracking of symptoms, fostering personalized care pathways and facilitating timely interventions. Healthcare professionals are increasingly utilizing wearable technology and patient-reported outcomes to customize treatment and optimize medication regimens without necessitating regular clinic visits. Integrated care models are gaining traction, enhancing patient adherence and engagement, while technology providers prioritize interoperability and intuitive interfaces. This trend not only strengthens patient-provider communication but also aligns with value-based care initiatives, markedly improving the management of chronic diseases like angina.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Angina Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Stable Angina
• Unstable Angina
• Microvascular Angina
• Prinzmetal Angina
• Others

Global Angina Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Beta-Blockers
• Calcium Channel Blockers
• Nitrates
• Angiotensin-Converting Enzyme Inhibitors
• Anti-Platelet Agents
• Others

Global Angina Market Size by Treatment Modality & CAGR (2026-2033)

• Market Overview
• Pharmacological Treatment
• Invasive Procedures
  • Angioplasty and Stenting
  • Coronary Artery Bypass Grafting
• Lifestyle Management
• Others

Global Angina Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare Settings
• Others

Global Angina Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Angina Market Size & CAGR (2026-2033)

• North America (Disease Type, Drug Class, Treatment Modality, End-User, Distribution Channel)
  • US
  • Canada
• Europe (Disease Type, Drug Class, Treatment Modality, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Drug Class, Treatment Modality, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Drug Class, Treatment Modality, End-User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Drug Class, Treatment Modality, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations